Global Health News - Week ending 18 October 2026

DRC Ebola outbreak becomes the second largest on record

The outbreak of Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo, confirmed in May 2026, had reached 8,728 confirmed cases including 4,205 deaths as of 6 October, with 2,269 people recovered, spread across 64 health zones in seven provinces. The crude case fatality ratio stood at 48.2 percent, more than 150 health workers were among the confirmed cases, and the outbreak was described as the second largest Ebola outbreak on record and the largest ever recorded in the country. It remained a Public Health Emergency of International Concern after the WHO emergency committee met for a second time on 18 August. Kenya reported its first confirmed case on 6 October, a traveller from the DRC via Uganda who later died, while Uganda's outbreak was declared over after 42 days without a new case. No vaccine is licensed specifically for Bundibugyo virus disease and no specific treatment exists, although a trial testing whether a vaccine developed for Zaire ebolavirus offers cross-protection had begun in the DRC.

Why it matters: The outbreak shows why emergency committee decisions, contact follow-up and health worker protection decide whether a filovirus outbreak stays contained, and why a vaccine for one Ebola virus species cannot be assumed to work against another.

Source: Australian Centre for Disease Control, 13 October 2026

World Top Stories

UN adopts pandemic prevention declaration as WHO presses for benefit-sharing annex

The World Health Organization welcomed the adoption by the UN General Assembly of a political declaration on pandemic prevention, preparedness and response, urging countries to turn its commitments into action. Member States had considered the declaration at the second high-level meeting on the topic on 25 September 2026 before referring it to the full Assembly. The declaration calls for sustained investment, stronger national, regional and global capacities, better monitoring systems, implementation of the amended International Health Regulations (2005), community empowerment, timely access to pathogens with equitable sharing of benefits, expanded local and regional manufacturing and research capacity, and sustainable financing. WHO pressed in particular for finalising the Pathogen Access and Benefit Sharing annex so that the WHO Pandemic Agreement can be opened for signature, ratified, and brought into force as international law, with the annex outcome to be considered at the World Health Assembly in May 2027 or earlier at a special session.

Why it matters: The declaration and the benefit-sharing annex will shape how vaccines, treatments and diagnostics are shared in the next pandemic, which is core knowledge for future pharmacists.

Source: World Health Organization, 12 October 2026

Gates Foundation and Wellcome Leap commit 100 million dollars to halving stillbirths

The Gates Foundation and Wellcome Leap announced Uzima, a stillbirth prevention programme, at the World Health Summit in Berlin, with each organisation contributing 50 million dollars over the first three years. The programme aims to show that stillbirth rates can be halved over a decade in selected countries, beginning with partners in sub-Saharan Africa, where almost half of the world's stillbirths occur. It will identify, validate and scale innovations that help families and health workers recognise risks earlier and respond to complications during pregnancy and childbirth, including diagnostic tools, AI-enabled ultrasound and screening, labour monitoring sensors, decision support tools, and patient navigation systems. Nearly 2 million babies are stillborn worldwide each year, about one every 17 seconds, and the funders say stillbirth prevention remains underfunded despite that scale. An initial package of innovations is expected by early 2027, with the first participating country partner to be announced in the coming months.

Why it matters: Stillbirth is a major but under-taught area of maternal and newborn health, and this programme shows how diagnostics and devices, not only medicines, are used to close the gap.

Source: Gates Foundation, 12 October 2026

Intermittent dialysis not shown to be as safe as continuous therapy in critically ill kidney patients

A multicentre, open-label, noninferiority trial in France found that starting critically ill adults with acute kidney injury on intermittent haemodialysis was not shown to be noninferior to continuous renal replacement therapy. The trial randomised 554 patients across intensive care units, with 535 included in the intention-to-treat analysis, and was stopped early after interim analyses showed a sustained signal of higher mortality with intermittent treatment. By day 90, a major adverse kidney event (death, dependence on renal replacement therapy, or creatinine more than 25 percent above baseline) had occurred in 78.1 percent of the intermittent group and 71.6 percent of the continuous group. Death by day 90 occurred in 63.1 percent and 53.5 percent respectively, with a hazard ratio of 1.30, and the authors cautioned that early stopping means the size of the mortality difference should be interpreted with care. Hypotension was the most common complication potentially related to the kidney injury or its treatment in both groups.

Why it matters: The trial is a clear example of a noninferiority design, early stopping for harm, and why the choice of dialysis modality in intensive care is a live clinical question.

Source: New England Journal of Medicine, 14 October 2026

WHO reconvenes experts to review one abortion care recommendation

The World Health Organization announced that it has moved its abortion care guideline to a living guideline format and has reconvened a subset of its Guideline Development Group to revisit one specific recommendation. The review concerns repeat dosing of the misoprostol-alone regimen for medical abortion at less than 12 weeks of pregnancy, listed as Recommendation 27b in the consolidated guideline. The reconvened experts, drawn from the group that informed the original guideline, will review synthesised evidence and formulate an updated recommendation, with their biographies published for public scrutiny. Members of the public may review the biographies and raise potential conflicts of interest with the WHO Secretariat by 29 October 2026. The targeted update leaves the rest of the guideline untouched while the review is under way.

Why it matters: Living guidelines are becoming the norm for fast-moving clinical areas, and pharmacy students should understand how single recommendations are updated without rewriting an entire guideline.

Source: World Health Organization, 14 October 2026

Long-acting HIV injections match daily pills in African adults with adherence challenges

A phase 3b, open-label, randomised trial in Kenya, South Africa and Uganda found that long-acting injectable cabotegravir plus rilpivirine was noninferior to daily oral dolutegravir-based therapy for adults living with HIV who had adherence or care-engagement challenges. The IMPALA trial enrolled 540 adults whose virus was already suppressed, assigning them to injections every eight weeks or to continued daily pills, and measured viral suppression below 50 copies per millilitre at week 48. Suppression was achieved in 91.0 percent of the injection group and 89.2 percent of the oral group, a difference within the trial's noninferiority margin. Confirmed virological failure occurred in five participants on injections and none on pills, and serious adverse events were reported in 4.1 percent and 3.0 percent respectively. Baseline drug resistance testing was not performed, and the 48-week follow-up cannot answer longer-term safety questions.

Why it matters: Long-acting antiretrovirals are a major adherence innovation, and this trial shows how noninferiority is tested in the populations who stand to benefit most.

Source: New England Journal of Medicine, 14 October 2026

WHO and cancer specialists join forces to improve global cancer care quality

The World Health Organization and the American Society of Clinical Oncology signed a collaboration agreement to improve access to quality cancer care internationally, with the joint aim of making quality a priority in the global cancer agenda and helping governments run programmes that improve access and survival. The partnership covers three areas: building core competencies in cancer care among health professionals, improving access to cancer clinical trials, and strengthening quality, accessibility and accountability in cancer services. Training will draw on ASCO's existing Global Courses, developed with WHO Member States and tailored to individual countries, while research activities will include virtual forums and virtual and in-person training. WHO's Global status report on cancer 2026 notes that cancer affects 92 percent of families around the world, with the heaviest health, social and economic burdens falling on low- and middle-income countries.

Why it matters: Cancer care quality and trial access are global pharmacy issues, from safe handling of oncology medicines to counselling patients on trial participation.

Source: World Health Organization, 15 October 2026

Eastern Mediterranean region renews commitment to a polio-free world

Health ministers and partners at the 73rd session of the WHO Regional Committee for the Eastern Mediterranean, held in Cairo from 13 to 15 October, reaffirmed their commitment to ending polio and building stronger immunisation systems. At the 15th meeting of the Regional Subcommittee for Polio Eradication and Outbreaks, delegates reviewed progress and the challenges that remain, noting that Afghanistan and Pakistan are still the only two countries where wild poliovirus is endemic, with transmission concentrated in southern Afghanistan and southern Khyber Pakhtunkhwa in Pakistan. Circulating variant poliovirus also continues to threaten parts of the region, including Somalia, Sudan and Yemen. Countries including Kuwait, Oman, Qatar, Saudi Arabia and the United Arab Emirates continue to support the effort through political leadership, technical cooperation and funding, and discussions also covered Afghanistan's Polio Legacy Challenge, which links eradication with stronger essential health services. Opening the session, WHO's Officer-in-Charge committed the organisation to protecting health delivery in the region despite a 14 percent budget cut.

Why it matters: Polio is down to its last two endemic countries, so students should follow how regional solidarity, surveillance and campaign quality decide whether eradication finishes or slips.

Source: Global Polio Eradication Initiative, 15 October 2026

INTERPOL and WHO sign health and security cooperation agreement

INTERPOL and the World Health Organization signed a cooperation agreement combining law enforcement expertise with public health leadership for joint action against threats at the intersection of health and security. The agreement covers exceptional situations such as suspected misuse of chemical or radioactive materials and unusual biological events, whether naturally occurring, accidental or deliberate, and coordination around major international events and mass gatherings. A second strand tackles trafficking of persons for organ removal and the illegal trade in human organs, tissues and cells. It also addresses illicit production and trade in goods that affect public health, including falsified medical products such as medicines, vaccines and medical devices, counterfeit personal protective equipment, unsafe or fraudulently labelled food and drink, and illegally produced alcohol. Cooperation will also support implementation of the WHO Framework Convention on Tobacco Control.

Why it matters: Falsified medicines and devices are a direct pharmacy concern, and this agreement shows how health agencies and police now work together against them.

Source: World Health Organization, 16 October 2026

Fractional yellow fever vaccine doses work in young children, Lancet trial finds

A phase 4, single-blind, randomised trial in Kampala, Uganda, found that fractional doses of the 17DD yellow fever vaccine were noninferior to the full dose in children aged 9 to 23 months. The trial, run at three public-sector health facilities, randomly assigned 1,784 children to a one-fifth dose, a one-half dose, or the standard full dose, with follow-up at four weeks, one year, and 13 to 48 months. Both fractional doses met the noninferiority criterion for initial seroconversion, measured by a 50 percent plaque reduction neutralisation test against a five percentage point margin, with no difference between the one-fifth and full doses and a difference of negative 0.17 percentage points between the one-half and full doses. The authors concluded that the results support using fractional doses in young children for outbreak response when supplies are short, an important finding because evidence in children under two years had previously been limited.

Why it matters: Fractional dosing is a key dose-sparing strategy during vaccine shortages, and this trial extends the evidence to the youngest children, who are often the hardest group to cover.

Source: The Lancet, 17 October 2026

South Asia

Only 3 stories met the bar this week.

Bangladesh measles death toll could now be as high as 1,144

Bangladesh's measles death toll could now be as high as 1,144, with most of those who died being children, according to a BMJ news report published as the country's deadly outbreak continued. The figures come amid an investigation into the national immunisation programme and the current outbreak. The latest government update, dated 8 October, showed that since mid-March there had been 201,625 suspected measles cases and 22,116 laboratory-confirmed cases. The combination of a four-figure death toll and more than 200,000 suspected cases marks an exceptionally severe outbreak. The report underlines how quickly measles can spread once immunity gaps open in a large population.

Why it matters: Measles is vaccine preventable, so a large outbreak with child deaths is a textbook case of what happens when routine immunisation coverage slips.

Source: BMJ, 12 October 2026

WHO calls for stronger action on road safety in South-East Asia

The World Health Organization called on Member States in the South-East Asia Region to strengthen action against road traffic deaths and injuries and to advance towards the global target of cutting them by at least 50 percent by 2030. In 2021, an estimated 1.19 million people died on roads worldwide, including around 330,000 in the South-East Asia Region, or 28 percent of the global total, while road traffic injuries are the leading cause of death among children and young people aged 5 to 29 years. Between 2010 and 2021, estimated road deaths in the region fell by just 2 percent, compared with 5 percent globally. Riders of powered two- and three-wheelers account for 46 percent of reported road deaths in the region, and together with pedestrians and cyclists they account for two-thirds of all reported deaths. The call came at the opening of a three-day Regional Meeting on Road Safety in New Delhi, which follows the July 2026 UN High-Level Meeting on Improving Global Road Safety and will work on leadership, data, safer roads and vehicles, enforcement, financing, and post-crash emergency, trauma and rehabilitation services.

Why it matters: Road traffic injury is a leading cause of death in young people and a major reason for emergency and trauma admissions, so prevention and post-crash care belong in any public health curriculum.

Source: WHO Regional Office for South-East Asia, 12 October 2026

India cuts TB cases by 21 percent and expands shorter drug-resistant treatment

India has cut yearly emerging tuberculosis cases by 21 percent between 2015 and 2024, compared with a global decline of 12 percent, according to a government backgrounder citing the WHO Global Tuberculosis Report 2025, while treatment coverage reached 92 percent against 78 percent globally and TB deaths fell by 28 percent over the same period. The gains are attributed to the intensified TB Mukt Bharat Abhiyaan, under which cumulative screenings crossed 281 million, more than 2 million people received TB preventive treatment, and 46,118 gram panchayats earned TB-free certification. Screening capacity expanded sharply, with a 34-fold increase in X-ray screening through handheld units, more than 500 AI-enabled handheld chest X-ray units deployed and 1,500 more being delivered, and over 9,800 rapid molecular testing facilities in place. For drug-resistant TB, the shorter BPaLM regimen (bedaquiline, pretomanid, linezolid, moxifloxacin) has cut treatment to six months, with more than 15,000 multidrug-resistant and rifampicin-resistant patients started on it. Treatment success under the campaign rose to 90 percent, above the global average of 88 percent.

Why it matters: India's TB programme is the world's largest, and its shift to shorter regimens, preventive treatment and community screening is directly relevant to pharmacy practice in infectious disease.

Source: Press Information Bureau, Government of India, 13 October 2026

Europe

Only 3 stories met the bar this week.

EMA recommends six new medicines, including an oral GLP-1 tablet

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended six medicines for approval at its 12 to 15 October meeting, including Foundayo (orforglipron), an oral GLP-1 receptor agonist tablet for weight management and type 2 diabetes in adults, Rasonque (daraxonrasib) for metastatic pancreatic adenocarcinoma in previously treated adults, and Yuviwel (navepegritide) for achondroplasia in children. Two biosimilars were recommended, Fovlussea (ranibizumab) for wet age-related macular degeneration and several retinal conditions and Neuzafy (filgrastim) for neutropenia, alongside Kizfizo (temozolomide), a hybrid medicine for glioblastoma in adults and malignant glioma in children. The committee also recommended extending the indications of five already authorised medicines and confirmed its refusal of Yartemlea (narsoplimab) for transplant-associated thrombotic microangiopathy after re-examination. It recommended making Nyxoid (naloxone) nasal spray for emergency treatment of known or suspected opioid overdose available without a medical prescription, and it declined to extend Mylotarg (gemtuzumab ozogamicin) to children aged 1 to under 18 with newly diagnosed acute myeloid leukaemia, agreeing instead that relevant study data be added to the product information.

Why it matters: CHMP opinions are the gateway to European approvals, and the naloxone switch shows how regulators widen access to emergency medicines.

Source: European Medicines Agency, 16 October 2026

Few Europeans know alcohol can cause breast cancer, WHO hub aims to close the gap

The World Health Organization's Regional Office for Europe launched an Alcohol Screening and Brief Interventions Hub with a built-in AI assistant during Breast Cancer Awareness Month, after survey data showed that only 15 percent of people across 14 countries knew alcohol could cause breast cancer, with awareness among women at just 21 percent. Alcohol causes at least seven types of cancer, including breast cancer, as well as cardiovascular and liver diseases, and in 2020 it was responsible for an estimated 39,200 new breast cancer cases across the WHO European Region. The hub offers the 10-question AUDIT screening test, interactive tools showing what counts as a standard drink and how alcohol affects health, and an assistant that answers only from a defined set of WHO evidence and implementation resources, shows the source behind every answer, and points users to a usable tool. The hub is a major product of the WHO and EU Evidence into Action Alcohol Project, co-funded by the European Union.

Why it matters: Alcohol is a modifiable cancer risk factor that patients rarely link to breast cancer, so screening and brief advice are core skills for community and hospital pharmacists.

Source: WHO Regional Office for Europe, 14 October 2026

Europe records its broadest West Nile virus season as mosquito-borne cases spread

Europe's 2026 mosquito-borne disease season was the broadest on record for West Nile virus, with 1,926 locally acquired human cases across 222 affected areas in 19 countries as of 14 October, according to the European Centre for Disease Prevention and Control's weekly threats report, with Italy most affected and Greece and France reporting their highest ever human case numbers. Belgium reported its first ever human West Nile infections, and activity had been declining since the August to September peak. Locally acquired chikungunya reached 163 cases in France and one in Italy, while locally acquired dengue reached 70 cases in Italy and six in France, and Spain reported four cases of Crimean-Congo haemorrhagic fever with no new cases in the past week. In September 2026, 342 mpox clade I cases were reported by 17 EU and EEA countries, continuing a summer increase, with transmission predominantly within networks of men who have sex with men, mostly among unvaccinated people, and generally mild severity with low hospitalisation.

Why it matters: Vector-borne diseases are moving into new European areas, so pharmacists need to recognise them, advise travellers, and understand why surveillance and mosquito control matter.

Source: European Centre for Disease Prevention and Control, 16 October 2026

North America

Only 4 stories met the bar this week.

FDA finalises guidance on manufacturing changes to biosimilars

The US Food and Drug Administration announced the availability of a final guidance for industry on postapproval manufacturing changes to biosimilar and interchangeable biosimilar products, finalising a draft issued on 23 July 2024. The guidance, a final Level 1 document issued jointly by the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research, answers commonly asked questions from applicants and other interested parties about postapproval manufacturing changes to biosimilars licensed under the Public Health Service Act. It supersedes the earlier draft and withdraws an earlier question and answer item from the separate guidance on biosimilar development. Comments on the guidance may be submitted at any time, and the document is filed under docket number FDA-2024-D-2581. The guidance gives manufacturers a single reference point for how to document and report changes to approved biosimilars, which matters because even small process changes can affect a biological product's quality.

Why it matters: Biosimilar manufacturing changes are routine but tightly regulated, and understanding comparability and reporting categories is essential for anyone working in biologics quality or regulation.

Source: US Food and Drug Administration, 13 October 2026

FDA expands bladder cancer treatment to papillary-only disease

The US Food and Drug Administration expanded the approval of Anktiva (nogapendekin alfa inbakicept-pmln), given with Bacillus Calmette-Guerin (BCG), to include adults with high-grade papillary-only bladder cancer that has not spread into the bladder muscle and has not responded to BCG. It is the first FDA-approved treatment specifically for BCG-unresponsive, high-grade papillary-only disease. The decision marks a new FDA approach, basing the expansion on evidence behind the earlier approval for carcinoma in situ, with or without papillary tumours, together with scientific similarities between that condition and high-grade papillary-only disease. The earlier approval rested on a trial of 77 adults in which 62 percent achieved a complete response, of whom 58 percent maintained the response for at least 12 months and 40 percent for at least 24 months. The FDA also said it is working towards finalising draft guidance on drug development for BCG-unresponsive non-muscle invasive bladder cancer.

Why it matters: The approval shows how regulators can extrapolate from one bladder cancer setting to a closely related one, a concept students will meet in drug evaluation and formulary work.

Source: US Food and Drug Administration, 14 October 2026

FDA approves first nonprescription apraclonidine eye drop for redness

The US Food and Drug Administration approved Brytly, apraclonidine ophthalmic solution 0.125 percent, as a new nonprescription eye drop for relief of eye redness due to minor irritations, the first nonprescription eye drop containing apraclonidine. The approval covers adults and children aged 12 years and older, and higher-concentration apraclonidine drops remain available by prescription to reduce eye pressure in glaucoma or after certain laser eye surgery. Consumers are advised to remove contact lenses before use and wait at least 10 minutes before reinserting them, to wait five minutes between different eye drops, and to stop use and ask a doctor if they experience eye pain, changes in vision, continued redness or irritation, or if the condition persists for more than three days or worsens. The approval was granted to Alcon.

Why it matters: The switch of a prescription-only active ingredient to nonprescription use is a classic pharmacy topic, covering counselling points and the limits of self-care.

Source: US Food and Drug Administration, 16 October 2026

FDA approves eye drop for presbyopia in adults

The US Food and Drug Administration approved a new indication for Ryzumvi (phentolamine ophthalmic solution 0.75 percent), an alpha-adrenergic blocker, for the treatment of presbyopia in adults, adding to its earlier approval for pharmacologically induced mydriasis. The updated labelling, revised in October 2026, records the new indication alongside the established use in reversing pupil dilation after eye examinations or procedures in adults and in children aged three years and older. In clinical trials for presbyopia involving 534 participants, the most common adverse reactions were conjunctival hyperaemia, reported in 21 percent of participants, and instillation site irritation, reported in 16 percent, with most reactions described as mild, transient and self-resolving. The label also notes that the product is not recommended when active ocular inflammation is present, because adhesions may form between the iris and the lens.

Why it matters: Presbyopia affects nearly every adult with age, so a new pharmacological option is relevant to community pharmacy, alongside the counselling points around eye inflammation and contact lens use.

Source: US Food and Drug Administration, 16 October 2026

Africa

Only 3 stories met the bar this week.

Egypt maintains gold tier status on the path to hepatitis C elimination

Egypt maintained its gold tier status on the path to elimination of hepatitis C, the WHO Director-General announced at the opening of the 73rd session of the WHO Regional Committee for the Eastern Mediterranean in Cairo on 13 October, with a certificate of verification to be presented to the health minister the following day. Egypt was the first country to reach gold tier status, in October 2023, after reducing hepatitis C prevalence from around 10 percent to under 0.38 percent through a national programme built on mass screening and treatment. Maintaining the status requires sustaining those gains rather than a one-off achievement, which is why WHO verifies progress rather than simply awarding it once. The announcement came alongside other regional milestones, including Libya and Tunisia eliminating trachoma as a public health problem, Kuwait and Qatar interrupting endemic transmission of measles and rubella, and Morocco achieving hepatitis B control.

Why it matters: Egypt's programme is the world's most cited hepatitis C elimination example, and it shows pharmacy students how screening, affordable treatment and political commitment combine to remove a virus from a population.

Source: World Health Organization, 13 October 2026

Kenya confirms second Ebola case, caught while already in quarantine

Kenya confirmed a second case of Ebola disease caused by Bundibugyo virus on 14 October, in a 39-year-old man who was a close family member of the country's first case and was already in quarantine under daily monitoring when he fell ill the previous day. He developed fever, fatigue and joint pains, was isolated immediately, and tested positive at both the National Virology Reference Laboratory and the KEMRI-CDC laboratory, with matching results, before being moved to a designated treatment centre for supportive care. The first case, a 40-year-old Kenyan man who had travelled from the Democratic Republic of the Congo through Uganda, arrived in Nairobi on 3 October, died on 5 October, and received a safe and dignified burial on 6 October. By 16 October, 130 contacts had been listed, with 92.3 percent in quarantine under daily clinical and temperature checks for 21 days from their last possible exposure, and WHO donated around 70,000 dollars of supplies including protective equipment, body bags, thermometers and test kits. Both cases are linked, and there is no evidence of spread in the wider community.

Why it matters: Kenya's response shows contact tracing and quarantine working as intended, with the second case caught while already monitored, which is exactly how imported filovirus cases are meant to be contained.

Source: WHO Regional Office for Africa, 16 October 2026

Diphtheria outbreaks reported in nine African countries

Diphtheria outbreaks were reported in nine African countries during 2026, with Nigeria recording the highest numbers followed by Chad, according to the European Centre for Disease Prevention and Control's weekly threats report, while numbers declined substantially in Mali but increased in Guinea. Transmission was described as widespread in Mali, Mauritania, Niger and Nigeria, with localised clusters in South Africa, a recent outbreak in Senegal, and localised clusters in Morocco. Diphtheria is a vaccine-preventable bacterial infection that can damage the heart and nerves, so sustained transmission points to gaps in routine immunisation and in access to antitoxin and antibiotics. The report sits alongside the Ebola updates for the same week, underlining how several vaccine-preventable and epidemic-prone diseases are circulating in the region at once.

Why it matters: Diphtheria is a classic example of a disease that returns when immunisation coverage falls, and students should know its prevention, treatment and the role of antitoxin.

Source: European Centre for Disease Prevention and Control, 16 October 2026

← Newer: Week ending 25 October 2026  ·  Older: Week ending 11 October 2026 →  ·  All Global Health News

Every story on this page was verified on its original source page. Coverage is pharma, medical, healthcare and community health only; no politics or finance.